Similarly, the results from the KENOTE-590, CheckMate 648 and ESCORT-1st clinical trials suggest a positive correlation between the PD-L1 expression level and the efficacy of PD-1 blockade plus chemotherapy in esophageal cancer [55–57]. The gene discussed is PDCD1; the disease is esophageal cancer.